ASX-listed Aroa Biosurgery gains on positive outlook
** Shares of Aroa Biosurgery ARX.AX rise as much as 8.3%
to A$0.780, their highest level since Nov. 10
** Soft-tissue regeneration co sees H2 FY24 product revenue
of NZ$41 mln ($25.01 mln)-NZ$44 mln, representing a 30%-40%
increase on H1 FY24
** Sees H2 FY24 normalised EBITDA profit of NZ$4-5 million,
compared to a NZ$2.7 mln loss in H1 FY24
** Stock down 33.3% YTD, as of last close
($1 = 1.6393 New Zealand dollars)
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Recent news on Aroa Biosurgery
See all newsAustralia-listed Aroa Biosurgery climbs as annual earnings beat guidance
Brief: Aroa Biosurgery Posts Adjusted EBITDA Of NZ$12.6 Million
Aroa Biosurgery climbs as prelim annual results beat outlook
Brief: Aroa Biosurgery Posts FY26 Prelim Total Revenue Of NZ$104 Million
Brief: Aroa Biosurgery Says Expects FY26 Revenue At Upper End Of NZ$92-100 Million